- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01793077
Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients (TREMODI)
Phase IV, Non-interventional, Prospective, Open Label, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients
Tremodi is an observational, non-interventional, prospective, open-label, non-comparative study that will collect real life data of a treatment with Depo-Eligard® in 3 different administrations in male prostate cancer patients.
Once the examining physician has decided on the therapeutic approach and if the selection criteria are fulfilled, he will propose the patient to participate in the study. An informed consent form will be collected for all participants in the study.
There are 2 possible study visits that coincide with a routine consultation, namely visit 1 (inclusion visit) and visit 2 (end of study visit). On both visits, Adverse Drug Reactions (adverse event caused by Depo-Eligard®) are collected and the patient will be asked to complete a Quality Of Life questionnaire (EORTC QLQ-C30). At visit 2, the examining physician will give a global evaluation of the treatment with Depo-Eligard® and assesses the treatment benefit of the patient.
Testosterone and Prostate Specific Antigen (PSA) blood values are collected during both visits, if available.
Study Overview
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Liège, Belgium, 4000
- Site: 38
-
-
Antwerp
-
Antwerpen, Antwerp, Belgium, 2018
- Site: 5
-
Antwerpen, Antwerp, Belgium, 2018
- Site: 8
-
Antwerpen, Antwerp, Belgium, 2018
- Site: 9
-
Antwerpen, Antwerp, Belgium, 2020
- Site: 14
-
Antwerpen, Antwerp, Belgium, 2200
- Site: 4
-
Merksem, Antwerp, Belgium, 2170
- Site: 33
-
Turnhout, Antwerp, Belgium, 2300
- Site: 1
-
-
Brussels Capital Region
-
Brussel, Brussels Capital Region, Belgium, 1090
- Site: 13
-
Bruxelles, Brussels Capital Region, Belgium, 1030
- Site: 23
-
Uccle, Brussels Capital Region, Belgium, 1180
- Site: 24
-
-
East Flanders
-
Aalst, East Flanders, Belgium, 9300
- Site: 32
-
Dendermonde, East Flanders, Belgium, 9200
- Site: 34
-
Gent, East Flanders, Belgium, 9000
- Site: 11
-
Oudenaarde, East Flanders, Belgium, 9700
- Site: 17
-
-
Flemish Brabant
-
Tienen, Flemish Brabant, Belgium, 3300
- Site: 18
-
-
Hainaut
-
La Louvière, Hainaut, Belgium, 7100
- Site: 39
-
-
Limburg
-
Sint Truiden, Limburg, Belgium, 3800
- Site: 37
-
-
Walloon Brabant
-
Lasne Chapelle Saint Lambert, Walloon Brabant, Belgium, 1380
- Site: 26
-
-
West Flanders
-
Ieper, West Flanders, Belgium, 8900
- Site: 21
-
Izegem, West Flanders, Belgium, 8870
- Site: 20
-
Kortijk, West Flanders, Belgium, 8500
- Site: 25
-
Oostende, West Flanders, Belgium, 8400
- Site: 31
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients having been prescribed Depo-Eligard® 7.5 mg - 22.5 mg - 45 mg in accordance with the terms of the marketing authorization.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Prostate Cancer patients
|
Subcutaneous
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluation of tolerability of treatment on a 4 point scale
Time Frame: Last Visit (after at least 180 days of treatment)
|
Last Visit (after at least 180 days of treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of Adverse Drug Reactions
Time Frame: Day 1 and Last Visit (after at least 180 days of treatment)
|
Day 1 and Last Visit (after at least 180 days of treatment)
|
|
Investigator satisfaction with treatment
Time Frame: Last Visit (after at least 180 days of treatment)
|
Last Visit (after at least 180 days of treatment)
|
|
Overall patient's assessment of treatment benefit
Time Frame: Last Visit (after at least 180 days of treatment)
|
Last Visit (after at least 180 days of treatment)
|
|
Changes in quality of life of subjects as measured by EORTC QLQ-C30
Time Frame: Day 1 and Last Visit (after at least 180 days of treatment)
|
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-C 30 (EORTC-QLQ-C30)
|
Day 1 and Last Visit (after at least 180 days of treatment)
|
Frequency of use of dosing schedules of Depo-Eligard® and the reasons for selecting a schedule
Time Frame: Day 1 and Last Visit (after at least 180 days of treatment)
|
Day 1 and Last Visit (after at least 180 days of treatment)
|
|
Efficacy of treatment
Time Frame: Day 1 and Last Visit (after at least 180 days of treatment)
|
(1) Changes in PSA and testosterone levels if available, (2) Change in disease symptoms and (3) Objective disease response
|
Day 1 and Last Visit (after at least 180 days of treatment)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BE-11-EGD-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Depo-Eligard®
-
Astellas Pharma IncCompleted
-
FHI 360Completed
-
Cancer Research AntwerpBayer; Veracyte, Inc.Recruiting
-
FHI 360Oregon Health and Science University; Asociación Dominicana Pro Bienestar de...CompletedContraceptionUnited States, Dominican Republic
-
Aragon Pharmaceuticals, Inc.Completed
-
HanAll BioPharma Co., Ltd.Completed
-
DendreonCompletedProstate Cancer | Prostatic Neoplasm | Prostatic AdenocarcinomaUnited States
-
UNICANCERAstellas Pharma IncActive, not recruiting
-
BayerCompletedMetastatic Castration-sensitive Prostate CancerCanada
-
National Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Stage IIA Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7United States